Can cancer brain metastases be treated using humanized monoclonal | 52580
Journal of Clinical Toxicology

Journal of Clinical Toxicology
Open Access

ISSN: 2161-0495

Can cancer brain metastases be treated using humanized monoclonal antibodies? A pilot pharmacological study

4th Global Summit on Toxicology

August 24-26, 2015 Philadelphia, USA

Guilhem Bousquet and Anne Janin

Scientific Tracks Abstracts: J Clin Toxicol

Abstract :

Therapeutic monoclonal antibodies have widely contributed to improving survival in metastatic cancers. However, patients are
at increased risk of developing central nervous system metastases, and the survival of patients with brain metastases remains
poor, challenging daily practice in medical oncology. The mechanisms limiting the use of therapeutic monoclonal antibodies for
the treatment of brain tumors are their inadequate transport from blood to brain through the blood-brain barrier. We performed
a sequential pharmacological pilot study in a young, 36-year-old woman with metastatic breast cancer who developed HER2-
overexpressing brain metastases resistant to standard treatment. With her informed consent, lumbar and ventricular reservoirs were
implanted for repeated intra-thecal injections of trastuzumab, an anti-HER2 monoclonal antibody. Close monitoring of trastuzumab
trough concentrations in the cerebrospinal fluid over 8 months enabled us to determine the intra-thecal drug administration schedule
required to stabilize the brain metastases on magnetic resonance imaging. Because of a high clearance from the cerebrospinal fluid,
and this result was unexpected, repeated injections of trastuzumab 3 times a week were required. This innovative scheme, guided by
individual pharmacology and mimicking a continuous perfusion, can be used for other patients. Apart from this therapeutic effect,
the rapid efflux of trastuzumab has not hitherto been described. FcRn receptors, expressed by the capillary endothelium of the bloodbrain
barrier, may be responsible for this efflux mechanism. Engineering of a F(ab’)2 fragment of humanized monoclonal antibody
against HER2 could prevent the binding of immunoglobulin to FcRn, and the mechanism of efflux.

Biography :

Guilhem Bousquet is a physician involved in medical oncology since 2005. After his clinical training as a fellowship in Clinical Oncology, he did his PhD thesis in Saint-
Louis Hospital in Paris, where he gained an expertise in pathology, xenograft models and pre-clinical pharmacology. He performed a Post-doctoral stay in Pasteur Institute
in Lille, and is now Associate Professor in Saint-Louis Hospital and member of the research unit UMR_S1165 University Paris 7/Inserm. His research team is involved in
experimental pharmacology and translational research using xenograft models of human fresh tumors. He has published 41 papers.